1. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD,
et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191–196. PMID:
20016485.
2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G,
et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153–158. PMID:
17344846.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S,
et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603–607. PMID:
22460905.
4. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S,
et al. Molecular target class is predictive of
in vitro response profile. Cancer Res 2010;70:3677–3686. PMID:
20406975.
5. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J,
et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104:19936–19941. PMID:
18077425.
6. Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q,
et al. Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 2012;131:2456–2464. PMID:
22422301.
7. Kim N, Park H, He N, Lee HY, Yoon S. QCanvas: an advanced tool for data clustering and visualization of genomics data. Genomics Inform 2012;10:263–265. PMID:
23346040.
8. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D,
et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011;39:D945–D950. PMID:
20952405.
9. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003;100:776–781. PMID:
12552134.
10. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000;21:379–385. PMID:
10688858.
11. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A,
et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214–218. PMID:
23770567.
12. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81–137. PMID:
10549356.
13. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M.
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157–2165. PMID:
17401424.
14. Cowey CL, Rathmell WK.
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009;11:94–101. PMID:
19216840.
15. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P,
et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene
PBRM1 in renal carcinoma. Nature 2011;469:539–542. PMID:
21248752.
16. Pawlowski R, Mühl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013;132:E11–E17. PMID:
22949125.
17. Lambert SR, Harwood CA, Purdie KJ, Gulati A, Matin RN, Romanowska M,
et al. Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene. Int J Cancer 2012;131:E216–E226. PMID:
22052591.